ATE504595T1 - Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz - Google Patents

Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz

Info

Publication number: ATE504595T1
Authority: AT; Austria
Prior art keywords: diabetes; obesity; treatment; hyperlipidemia; hyperglycemia
Prior art date: 2005-01-04

Application number

AT05784419T

Other languages

English (en)

Inventor

Yu Huang

Xu Chen

Original Assignee

Generon Shanghai Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-01-04

Filing date

2005-08-08

Publication date

2011-04-15

2005-08-08 Application filed by Generon Shanghai Corp filed Critical Generon Shanghai Corp

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE504595T1 publication Critical patent/ATE504595T1/de

Links

206010012601 diabetes mellitus Diseases 0.000 title abstract 3
208000031226 Hyperlipidaemia Diseases 0.000 title abstract 2
208000008589 Obesity Diseases 0.000 title abstract 2
235000020824 obesity Nutrition 0.000 title abstract 2
206010022489 Insulin Resistance Diseases 0.000 title 1
201000001421 hyperglycemia Diseases 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
201000008980 hyperinsulinism Diseases 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT05784419T 2005-01-04 2005-08-08 Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz ATE504595T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CNB2005100231030A CN100515491C (zh)	2005-01-04	2005-01-04	白介素-22的医药用途
PCT/US2005/028186 WO2006073508A1 (en)	2005-01-04	2005-08-08	Use of il-22 for the treatment of conditions of metabolic disorders

Publications (1)

Publication Number	Publication Date
ATE504595T1 true ATE504595T1 (de)	2011-04-15

Family

ID=35066920

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05784419T ATE504595T1 (de)	2005-01-04	2005-08-08	Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz

Country Status (9)

Country	Link
US (4)	US20100015086A1 (de)
EP (1)	EP1841781B1 (de)
JP (1)	JP5221959B2 (de)
CN (1)	CN100515491C (de)
AT (1)	ATE504595T1 (de)
AU (1)	AU2005323392B2 (de)
CA (1)	CA2592943C (de)
DE (1)	DE602005027400D1 (de)
WO (1)	WO2006073508A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103463096B (zh) *	2006-01-27	2016-03-16	耶鲁大学	胃酸分泌的快速作用抑制剂
CN101361968B (zh) *	2007-08-06	2011-08-03	健能隆医药技术（上海）有限公司	白介素-22在治疗脂肪肝中的应用
CN102348463B (zh) *	2009-01-12	2014-05-07	健能隆医药技术（上海）有限公司	白介素-22在预防和/或治疗多器官功能障碍综合症(mods)中的用途
CN102260343A (zh)	2010-05-25	2011-11-30	健能隆医药技术（上海）有限公司	重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380091A (zh)	2010-08-31	2012-03-21	健能隆医药技术（上海）有限公司	白介素-22在治疗病毒性肝炎中的应用
AU2012289433B2 (en)	2011-07-25	2017-07-27	Evive Biotechnology (Shanghai) Ltd	Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
CN103182072B (zh)	2011-12-27	2017-05-03	健能隆医药技术（上海）有限公司	白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
US20150157692A1 (en) *	2012-05-23	2015-06-11	The University Of Chicago	Methods of treating obesity
ES2676023T3 (es)	2013-03-15	2018-07-16	F. Hoffmann-La Roche Ag	Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
CN104623639A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	白介素22二聚体在制备治疗胰腺炎药物中的应用
CN104623637A (zh)	2013-11-07	2015-05-20	健能隆医药技术（上海）有限公司	Il-22二聚体在制备静脉注射药物中的应用
DK3149049T3 (da)	2014-05-27	2023-01-23	Univ Queensland	Il-22 til anvendelse til behandling af stofskiftesygdomme
US11510966B2 (en)	2016-04-15	2022-11-29	Evive Biotechnology (Shanghai) Ltd	Use of IL-22 in treating necrotizing enterocolitis
EP3802596A4 (de)	2018-06-05	2022-07-20	BioAtla, Inc.	Anti-il-22-antikörper, antikörperfragmente, deren immunkonjugate und verwendungen davon
US12527875B2 (en)	2020-02-19	2026-01-20	Evive Biotechnology (Shanghai) Ltd	Methods for treating graft versus host disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4849227A (en) *	1986-03-21	1989-07-18	Eurasiam Laboratories, Inc.	Pharmaceutical compositions
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
ES2131122T3 (es) *	1992-10-01	1999-07-16	Schering Corp	Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
US5541087A (en) *	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
US6551799B2 (en) *	1999-12-07	2003-04-22	Genentech, Inc.	Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6982320B2 (en) *	1998-03-19	2006-01-03	Human Genome Sciences, Inc.	Cytokine receptor common gamma chain like
US20010023070A1 (en) *	1998-05-29	2001-09-20	Reinhard Ebner	Interleukins-21 and 22
US7081528B2 (en) *	1998-10-26	2006-07-25	Ludwig Institute For Cancer Research	Isolated nucleic acid molecules encoding T cell derived inducible factors
US20050271619A1 (en) *	1998-10-26	2005-12-08	Laure Dumoutier	Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
US6331613B1 (en) *	1998-10-26	2001-12-18	Ludwig Institue For Cancer Research	Isolated nucleic acid molecules which encode T cell inducible factors (TIFS), the proteins encoded, and uses thereof
US6274710B1 (en) *	1998-10-26	2001-08-14	Ludwig Institute For Cancer Research	Antibodies which specifically bind T Cell inducible factors (TIFs)
US6939545B2 (en) *	1999-04-28	2005-09-06	Genetics Institute, Llc	Composition and method for treating inflammatory disorders
US20030012788A1 (en) *	2000-07-27	2003-01-16	Jean-Christophe Renauld	Method for influencing kinase pathways with IL-22
US20030023033A1 (en) *	2001-07-26	2003-01-30	Laure Dumoutier	Novel class II cytokine receptors and uses thereof
US20030235561A1 (en) *	2002-06-25	2003-12-25	Cell Based Delivery Inc.	Vascularized organized tissues and uses thereof
US20040236075A1 (en) *	2002-07-24	2004-11-25	Laure Dumoutier	Novel glass II cytokine receptors, and uses thereof
DE602004028347D1 (de) *	2003-03-24	2010-09-09	Zymogenetics Inc	Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung

2005
- 2005-01-04 CN CNB2005100231030A patent/CN100515491C/zh not_active Expired - Lifetime
- 2005-08-08 JP JP2007549350A patent/JP5221959B2/ja not_active Expired - Fee Related
- 2005-08-08 DE DE602005027400T patent/DE602005027400D1/de not_active Expired - Lifetime
- 2005-08-08 EP EP05784419A patent/EP1841781B1/de not_active Expired - Lifetime
- 2005-08-08 AU AU2005323392A patent/AU2005323392B2/en not_active Ceased
- 2005-08-08 AT AT05784419T patent/ATE504595T1/de not_active IP Right Cessation
- 2005-08-08 US US11/813,286 patent/US20100015086A1/en not_active Abandoned
- 2005-08-08 CA CA2592943A patent/CA2592943C/en not_active Expired - Lifetime
- 2005-08-08 WO PCT/US2005/028186 patent/WO2006073508A1/en not_active Ceased
2007
- 2007-11-16 US US11/941,093 patent/US7696158B2/en not_active Expired - Lifetime
- 2007-11-16 US US11/941,095 patent/US7666402B2/en not_active Expired - Lifetime
- 2007-11-16 US US11/941,092 patent/US7718604B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US20080069798A1 (en)	2008-03-20
AU2005323392A1 (en)	2006-07-13
US7696158B2 (en)	2010-04-13
AU2005323392B2 (en)	2011-08-18
CA2592943C (en)	2015-11-24
JP2008526740A (ja)	2008-07-24
US7666402B2 (en)	2010-02-23
DE602005027400D1 (de)	2011-05-19
US20080069799A1 (en)	2008-03-20
EP1841781B1 (de)	2011-04-06
WO2006073508A1 (en)	2006-07-13
EP1841781A4 (de)	2008-04-16
US20100015086A1 (en)	2010-01-21
US7718604B2 (en)	2010-05-18
CA2592943A1 (en)	2006-07-13
CN1679918A (zh)	2005-10-12
JP5221959B2 (ja)	2013-06-26
US20080138314A1 (en)	2008-06-12
EP1841781A1 (de)	2007-10-10
CN100515491C (zh)	2009-07-22

Similar Documents

Publication	Publication Date	Title
WO2010049678A3 (en)	2010-08-26	Treatment of energy utilization diseases
ATE504595T1 (de)	2011-04-15	Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
EP1758597A4 (de)	2008-02-27	Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
HUE038279T2 (hu)	2018-10-29	Klotho-béta-agonista antitest cukorbetegség vagy inzulinrezisztencia kezelésében történõ alkalmazásra
NO20084380L (no)	2008-12-16	Neuromedin U-reseptoragonister og anvendelser derav
WO2007100535A3 (en)	2008-03-20	Oxyntomodulin derivatives
WO2009051706A3 (en)	2009-12-17	Peptide compounds for treating obesity and insulin resistance
EA200802184A1 (ru)	2009-06-30	Фармацевтические композиции с ингибиторами dpp iv
ECSP10010007A (es)	2010-07-30	Tratamiento con ligandos alpha-7-selectivos
CL2008001125A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2008001126A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
ATE407927T1 (de)	2008-09-15	3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
CL2009000173A1 (es)	2010-02-12	Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
CL2007002642A1 (es)	2008-07-18	Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
IL200660A (en)	2015-09-24	Methods for producing 2,1-propanediol and e. coli is adapted to use these methods
CL2007001886A1 (es)	2009-11-10	Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.
ZA200711105B (en)	2009-08-26	Novel physiological substance nesfatin substance relevant thereto, and use of the substances
DE602005015841D1 (de)	2009-09-17	Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
CL2008003182A1 (es)	2009-11-27	Compuestos derivados de 1,2,4-triazol-3-amino; composicion farmaceutica; y su uso en el tratamiento del dolor, reflujo gastroesofagico, ansiedad, sindrome del intestino irritable.
ATE496890T1 (de)	2011-02-15	Pyridinderivate für die behandlung von stoffwechselstörungen, die mit insulinresistenz oder hyperglykämie in zusammenhang stehen
BRPI0908569A2 (pt)	2015-09-22	estimuladores de secreção de insulina derivados de piridopirazinonas, métodos para obtê-los e uso dos mesmos para o tratamento de diabetes
CY1116166T1 (el)	2017-02-08	Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
WO2006007400A9 (en)	2009-04-09	Methods of diagnosing and treating obesity, diabetes and insulin resistance
DK2193789T3 (da)	2013-05-21	Anvendelse af 3,5-dihydroxytoluen eller derivater deraf i fremstillingen af medicin og funktionelle fødevarer til behandling eller forebyggelse af depression
DE602005001576D1 (de)	2007-08-23	Pyrrolidin- und thiazolidin-Derivate, deren Darstellung und Anwendung zur Behandlung von Hyperglykämie und Typ II Diabetes

Legal Events

Date	Code	Title	Description
2011-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties